Biliary Tract Cancer Clinical Trials in New York, New York
5 studies are recruiting for biliary tract cancer in New York, New York right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.
Search these by distance from you
Studies now recruiting
-
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)
Researchers want to learn if sacituzumab tirumotecan (MK-2870) alone or with other treatments can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are either advanced (the cancer has spread to other parts of the body), or unresectable (the cancer cannot be removed with surg…
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Laura and Isaac Perlmutter Cancer Center at NYU Langone ( Site 0324), New York, New York
- Locations
- 55 in total
- Run by
- Merck Sharp & Dohme LLC
-
Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer
The purpose of this study is to evaluate the efficacy and safety of Zanidatamab plus CisGem (Cisplatin and Gemcitabine) with or without the addition of a programmed death protein 1/ligand-1 (PD-1/L1) inhibitor (physician's choice of either Durvalumab or Pembrolizumab, where approved under local reg…
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Memorial Sloan Kettering Cancer Centers, New York, New York
- Locations
- 185 in total
- Run by
- Jazz Pharmaceuticals
-
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
- Stage
- Phase 1
- Ages
- 18 and older
- Site
- Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York
- Locations
- 26 in total
- Run by
- SystImmune Inc.
-
A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02)
The purpose of this study is to measure the efficacy and safety of rilvegostomig with gemcitabine plus cisplatin vs. durvalumab with gemcitabine plus cisplatin as first line treatment for patients with advanced BTC.
- Stage
- Phase 3
- Ages
- 18 and older
- Site
- Research Site, New York, New York
- Locations
- 177 in total
- Run by
- AstraZeneca
-
Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer
The purpose of this study is to measure the efficacy and safety of T-DXd with rilvegostomig or T-DXd monotherapy compared with gemcitabine plus cisplatin and durvalumab in patients with advanced treatment naïve HER2-expressing BTC.
- Stage
- Phase 3
- Ages
- 18 to 99
- Site
- Research Site, New York, New York
- Locations
- 269 in total
- Run by
- AstraZeneca
How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.
What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.
Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.